Systemic Lupus Erythematosus Clinical Trials

44 studies are recruiting for systemic lupus erythematosus in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 2

1. Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

   The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   Pinnacle Research Group Llc, Anniston, Alabama

   Locations

   143 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06133972 on ClinicalTrials.gov

2. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

   This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), healthy participants of Chinese and Japanese descent (Part C), and participants with interstitial lung diseas…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   GSK Investigational Site, Aurora, Colorado

   Locations

   28 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06576271 on ClinicalTrials.gov

3. US Zamto-cel Autoimmune Diseases

   AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin

   Run by

   Miltenyi Biomedicine GmbH

   See if you can join NCT06708845 on ClinicalTrials.gov

4. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

   This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of …

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04751396 on ClinicalTrials.gov

5. Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

   The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in pat…

   Stage

   Not phased

   Ages

   18 to 45

   Site

   NYU Langone Medical Center/Hospital for Joint Diseases, New York, New York

   Locations

   10 in total

   Run by

   Hospital for Special Surgery, New York

   See if you can join NCT00198068 on ClinicalTrials.gov

6. Alnuctamab for Refractory SLE (LATTE Study)

   This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

   Stage

   Phase 1

   Ages

   18 to 60

   Site

   Icahn School of Medicine at Mount Sinai, New York, New York

   Run by

   Icahn School of Medicine at Mount Sinai

   See if you can join NCT07219563 on ClinicalTrials.gov

7. Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

   The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN. The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the dis…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   MD Anderson Cancer Center, Houston, Texas

   Locations

   2 in total

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT06434363 on ClinicalTrials.gov

8. A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

   The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Climb Bio Investigative Site #100104, Allen, Texas

   Locations

   18 in total

   Run by

   Climb Bio, Inc.

   See if you can join NCT07011043 on ClinicalTrials.gov

9. Rheumatology Patient Registry and Biorepository

   To facilitate clinical, basic science, and translational research projects involving the study of rheumatic diseases.

   Stage

   Not phased

   Ages

   18 to 99

   Site

   Yale New Haven Hospital, New Haven, Connecticut

   Run by

   Yale University

   See if you can join NCT04402086 on ClinicalTrials.gov

10. CorEvitas Systemic Lupus Erythematosus (SLE) Drug Safety and Effectiveness Registry

    Prospective, observational registry for subjects with SLE under the care of a rheumatology provider. Longitudinal data are collected from both subjects and their treating rheumatology provider during routine clinical encounters using a structured and standardized data collection method.

    Stage

    Not phased

    Ages

    18 and older

    Site

    CorEvitas, Waltham, Massachusetts

    Run by

    CorEvitas

    See if you can join NCT06804057 on ClinicalTrials.gov

11. Duke Lupus Registry

    Lupus is a systemic autoimmune disease that can present with many varied symptoms, including joint pain, fevers, kidney disease, and rashes. Lupus can affect anyone, but it is most common in younger women. The Duke Lupus Registry will collect information and blood samples from patients with lupus (…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Duke University Medical Center, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT00512694 on ClinicalTrials.gov

12. Maternal Autoimmune Disease Research Alliance (MADRA) Registry

    This multi-site registry, centered at Duke University, will enroll pregnant women with autoimmune and rheumatologic diseases. The main goal of MADRA is to identify ways to improve the health of women with rheumatic diseases and their babies during pregnancy. Prior studies demonstrate the importance…

    Stage

    Not phased

    Ages

    Any age

    Site

    Duke University, Durham, North Carolina

    Run by

    Duke University

    See if you can join NCT03276923 on ClinicalTrials.gov

13. Safety of the Herpes Zoster Subunit Vaccine in Lupus

    This randomized, double-blind, placebo-controlled, non-inferiority crossover study will evaluate the Herpes Zoster Sunbit (HZ/su) vaccine in SLE patients in order to evaluate safety and immunogenicity in patients with variable baseline clinical activities, ages and immunosuppressant exposures. The …

    Stage

    Phase 4

    Ages

    18 to 90

    Site

    NYU Langone Health, New York, New York

    Locations

    2 in total

    Run by

    NYU Langone Health

    See if you can join NCT05559671 on ClinicalTrials.gov

14. REACT-01: Reversing Autoimmunity Through Cell Therapy

    This is a phase 1, open-label, non-randomized study enrolling pediatric and young adult research participants with treatment-refractory Systemic Lupus Erythematosus (SLE), to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cel…

    Stage

    Phase 1

    Ages

    2 to 30

    Site

    Seattle Children's Hospital, Seattle, Washington

    Run by

    Seattle Children's Hospital

    See if you can join NCT06465147 on ClinicalTrials.gov

15. Safety and Efficacy of ONT01 in Lupus

    ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE. The study also looks at …

    Stage

    EARLY_Phase 1

    Ages

    18 and older

    Site

    Hospital for Special Surgery, New York, New York

    Run by

    Hospital for Special Surgery, New York

    See if you can join NCT07107659 on ClinicalTrials.gov

16. Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

    A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purgi…

    Stage

    Phase 2

    Ages

    8 to 25

    Site

    Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

    Run by

    Stephan Grupp MD PhD

    See if you can join NCT05029336 on ClinicalTrials.gov

17. UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients

    The goal of this clinical trial is to evaluate the safety and effectiveness of UC-MSCs in adults with systemic lupus erythematosus (SLE). The main questions this study aims to answer are: 1. Can UC-MSCs improve kidney function and reduce SLE disease activity? 2. Are UC-MSCs safe and well-tolerated …

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Medical University of South Carolina, Charleston, South Carolina

    Run by

    LiveKidney.Bio

    See if you can join NCT06737380 on ClinicalTrials.gov

18. BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus

    This phase 1 study seeks to examine the safety and recommended phase 2 dose (RP2D) of BAFF-ligand CAR-T cells (LMY-920) in adult patients with refractory systemic lupus erythematosus (SLE). It is hypothesized that BAFF CAR-T cells will be safe and will improve SLE disease activity scores.

    Stage

    Phase 1

    Ages

    18 to 65

    Site

    Nationwide Children's, Columbus, Ohio

    Run by

    Luminary Therapeutics

    See if you can join NCT06340750 on ClinicalTrials.gov

19. Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

    This study will evaluate the safety and activity of AB-101 in combination with rituximab in B-cell associated autoimmune diseases where rituximab is currently FDA approved (e.g., Rheumatoid Arthritis (RA), Pemphigus Vulgaris (PV), Granulomatosis with polyangiitis (GPA)/microscopic polyangiitis (MPA…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    IRIS Research and Development, LLC, Plantation, Florida

    Run by

    IRIS Research and Development, LLC

    See if you can join NCT06581562 on ClinicalTrials.gov